am-630 and Prostatic-Neoplasms

Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.. WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner. Mechanistic studies revealed these effects were mediated through a pathway involving cell cycle regulators p27, Cdk4, and pRb. Pre-treatment with a CB. The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.

Topics: Animals; Apoptosis; Benzoxazines; Cannabinoid Receptor Antagonists; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Male; Mice; Mice, Nude; Morpholines; Naphthalenes; Neoplasm Invasiveness; PC-3 Cells; Prostatic Neoplasms; Random Allocation; Receptor, Cannabinoid, CB2; Resting Phase, Cell Cycle; Xenograft Model Antitumor Assays